Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Clinical Trial Approval Notification for Additional Indication of Anti-TSLP Monoclonal Antibody

Time:2026-04-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Re-appointment of The Auditor

Time:2026-03-31

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Proposed 2025 Profit Distribution Plan of the Company

Time:2026-03-31

Ad hoc announcement pursuant to Art. 53-JCARE 2025 Annual Report

Time:2026-03-31

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial of a New-Generation Inhaled Corticosteroids

Time:2026-03-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval Notice for Clinical Trial of Brexpiprazole Microspheres for Injection

Time:2026-03-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Progress of the Proposed Public Tender of the Acquisition of Equity Interests in Vietnam IMP by Controlled Subsidiary Livzon Group

Time:2026-03-06

Ad hoc announcement pursuant to Art. 53 LR-Joincare Pharmaceutical Group Industry Co., Ltd. Announcement on the Appointment of Vice President of the Company

Time:2026-01-16

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Lecankitug Injection Included in the Priority Review Process

Time:2026-01-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Subsidiary Obtaining PICS GMP Certification

Time:2025-12-30

< 1234...14 >